| (19) |
 |
|
(11) |
EP 2 116 230 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
29.09.2010 Bulletin 2010/39 |
| (43) |
Date of publication A2: |
|
11.11.2009 Bulletin 2009/46 |
| (22) |
Date of filing: 16.11.2004 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK
TR |
|
Designated Extension States: |
|
AL HR LT LV MK YU |
| (30) |
Priority: |
17.11.2003 US 520605 P
15.11.2004 US 988716
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
04811199.1 / 1689363 |
| (71) |
Applicant: Intarcia Therapeutics, Inc |
|
Hayward CA 94545 (US) |
|
| (72) |
Inventors: |
|
- Eliaz, Rom E.
Sunnyvale, CA 94087 (US)
- Zahng, Yuanpeng
Cupertino, CA 95014 (US)
- Rohloff, Catherine Manya
Los Altos, CA 94024 (US)
- Weeks, Eric William
Hayward, CA 94545 (US)
- Gunjan, Junnarkar
Palo Alto, CA 94303 (US)
|
| (74) |
Representative: Walton, Seán Malcolm et al |
|
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS
London
EC2V 8AS (GB) |
|
| |
|
| (54) |
Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
(57) A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic
drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous
liquid solvent, and a pharmaceutically active agent